FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HORAK IVAN D (Last) (First) (Middle) C/O ENZON PHARMACEUTICALS, INC. 685 ROUTE 202/206 (Street) BRIDGEWATER NJ 08807							2. Issuer Name and Ticker or Trading Symbol ENZON PHARMACEUTICALS INC [ENZN] 3. Date of Earliest Transaction (Month/Day/Year) 11/23/2008 4. If Amendment, Date of Original Filed (Month/Day/Year)										tionship of Reporting Person(s) to Issuer all applicable) Director 10% Owner Officer (give title Other (specify below) below) EVP, R&D, Chief Scientific Off ridual or Joint/Group Filing (Check Applicable) Form filed by One Reporting Person Form filed by More than One Reporting Person				Owner (specify Off Applicable
(City)	(Si		Zip)																		
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day						on 2A. Deemed Execution Date,				3. Transaction Code (Instr. 8)			occurities Acquired osed Of (D) (Instr. 5)			(A) or 3, 4 Secur Benet Owne Follor Repo		nount of (rities Ificially (rities Ifi		Ownership rm: Direct or irect (I) str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
						Code	V	Amou		(D) Pr			Transaction((Instr. 3 and								
Common	2008	2008				M		2,2	50	A)	108,250			D					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date curity or Exercise (Month/Day/Year)		Execution Date, T if any C (Month/Day/Year) 8		4. Transact	ansaction ode (Instr.		Number (i) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Date Exercisable : Expiration Date Month/Day/Year)			Amount of Securities Underlying Derivative Security (Instr. : and 4) Amount or Numb of			8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	\$0	11/23/2008			M	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	(A)	2,250		23/2008	11/2	23/2008	Commo Stock		250	(1)		5,250		D	

Explanation of Responses:

1. Each restricted stock unit was the economic equivalent of one share of the issuer's common stock. The reporting person settled the vested restricted stock units for shares of the issuer's common stock.

/s/ Craig A. Tooman, Attorney-In-Fact 11/25/2008

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).